Related Experiment Videos
Staphylococcal bacteraemia and endocarditis and fusidic acid
1Department of Microbiology, United Medical School of Guy's Hospital, London, UK.
The Journal of Antimicrobial Chemotherapy
|February 1, 1990
Summary
Intravenous fusidic acid is linked to jaundice in Staphylococcus aureus infections. Switching to oral administration significantly reduces this risk, making it a safer option for patients.
Area of Science:
- Pharmacology
- Infectious Diseases
- Hepatology
Background:
- Fusidic acid is a critical antibiotic for Staphylococcus aureus infections.
- Previous reports indicated an association between intravenous fusidic acid and jaundice.
- Concerns about drug-induced liver injury necessitate evaluating administration routes.
Purpose of the Study:
- To assess the incidence of jaundice associated with fusidic acid use.
- To compare jaundice rates between intravenous and oral formulations.
- To evaluate the impact of administration route changes on patient outcomes.
Main Methods:
- Retrospective analysis of patient data on fusidic acid use for Staphylococcus aureus infections.
- Comparison of jaundice incidence in patients receiving intravenous versus oral fusidic acid.
- Review of patient records for adverse events, specifically jaundice.
Main Results:
- The incidence of jaundice decreased from 48% to 17% with reduced intravenous fusidic acid use.
- Jaundice rates were 13% (earlier) and 6% (recent) for oral-only administration.
- Intravenous administration was reduced from 71% to 25% of patients.
Conclusions:
- Reducing intravenous fusidic acid use significantly lowers the risk of jaundice.
- Oral fusidic acid is a safer alternative, with lower associated jaundice incidence.
- Intravenous fusidic acid should be avoided when possible due to its hepatotoxicity.